Molecular Partners AG Sponsored ADR MOLN 深 沪
等待开盘 02-05 09:30:00 美东时间
4.40
-0.105
-2.33%
华盛通- 最 高4.625
- 今 开4.49
- 成交量 4136股
- 最 低 4.33
- 昨 收 4.505
- 总市值 1.65亿
- 52周最高 5.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.36
- 委 比 -99.28%
- 总股本 3739.24万
- 历史最高 32.04
- 量 比 0.61
- 振 幅 6.55%
- 历史最低 3.32
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13
HC Wainwright & Co. analyst Robert Burns initiates coverage on Molecular Partners (NASDAQ:MOLN) with a Buy rating and announces Price Target of $13.
01-27 19:16
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Molecular Partners Q3 EPS $(1.65) Misses $(0.46) Estimate
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.46) by 258.7 percent.
2025-10-31 05:49
JP Morgan Maintains Neutral on Molecular Partners, Lowers Price Target to $4
JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from $4.5 to $4.
2025-09-03 23:18
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
2025-08-26 20:09
Molecular Partners Q2 EPS $(0.67) Down from $(0.56) YoY
Molecular Partners (NASDAQ:MOLN) Q2 EPS $(0.67) Down from $(0.56) YoY
2025-08-26 04:06
Molecular Partners To Reduce Workforce By Up To 24%
In H1 2025, Molecular Partners undertook a strategic review of its operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a
2025-08-26 04:02
